This Stock is Up 650% in Five Years

You're receiving this email as part of your subscription to Michael Robinson's Trend Trader Daily [Unsubscribe](. [Trend Trader Daily] This Stock is Up 650% in Five Years Tuesday, February 7, 2023 When it comes to fields like science and health care, some acronyms are more well-known than others. For example, you're probably familiar with the FDA (Food and Drug Administration) and its role approving and regulating new drugs and devices. And given recent history, you're probably also familiar with the CDC (Centers for Disease Control and Prevention). But if you want to make big money as investors in these fields, there's another acronym you need to know about. It's an organization targeting a market that's on its way to becoming worth $108 billion, and its job is to help biotech companies and cutting-edge drugs get to market faster and cheaper. I'm referring to CROs, which stands for contract research organizations. Make no mistake: These are vital firms that do the heavy lifting for clinical work, the kind that not even some of the biggest companies in the world can do on their own. Today, I want to tell you about a leading CRO business, a company on pace to double its earnings in just over two years... Which means an investment in it could soon double, too. > ADVERTISEMENT < The REAL Top Stocks for 2023 (Are not what you think) Financial news legend Herb Greenberg has gone public with his top 9 stocks for 2023... And they’re NOT what you’d expect. Herb says the market is entering a strange new phase… And warns that millions of Americans who fail to make this transition could see more losses. [Click here to see the type of stocks Herb thinks will weather inflation and pay investors long-term gains](. The Need for CROs Launching new medicine is a time-intensive process. The amount of research needed to find and test new chemicals is astounding. According to a report on drug development from the Biotechnology Innovation Organization, the industry's advocacy association, it takes almost 11 years on average to get a drug from Phase 1 trials through regulatory approval. And that's if the drug successfully makes it past trials in the first place. Less than 8% of drugs in Phase 1 trials end up getting approved. From a public health perspective, this rigorous process isn't a bad thing. Many drugs and therapies may seem effective at first glance, but they turn out to be ineffective, or even unsafe. Weeding these drugs out is a critical part of the approval process. As you might imagine, all this time spent developing and testing new drugs is also quite expensive. According to medical experts at FTLOScience, a science-focused education platform, getting a new drug to market costs about $2 billion. That's where CROs enter the picture. These are companies that biotech and pharmaceutical firms contract for specialized research, monitoring, and other services. And one CRO is a go-to resource... Demand for This Firm is About to Explode This company specializes in providing services for smaller biotech firms that tend to achieve the biggest breakthroughs in medicine. In fact, 85% of this company's revenues come from these smaller firms, often where the most exciting research happens. Notably, while funding for biotech overall may be pulling back, things are looking good for the company I'm focusing on. You see, while Covid created a huge influx of money into the pharma space, many non-Covid research projects were shelved. That means the biotech industry now has a huge number of well-developed, promising drugs in its pipeline. And as a result, a lot of biotech companies are about to send their drugs through trials and the regulatory approval process. Combine that with pent-up demand for non-Covid-related breakthroughs, and demand for this company's research, regulatory, and clinical trial services is about to explode. Customers Need This Company Keep in mind that smaller biotech companies are often just a scrappy group of scientists and engineers. Their expertise is in finding or inventing products and technologies. Switching gears to organize a safety trial involving hundreds of people isn't their strong suit. It's just not what they do. And chances are, it would distract from their primary duties. That's why they reach out to CROs to handle this stuff for them. CROs are well versed in running safety trials with medical centers. They have entire networks of hospitals, clinics, and national regulatory agencies. And the company I'm recommending is no exception. When it comes to trials, this company knows all the pitfalls, knows how to handle the paperwork, and knows how to meet deadlines. Furthermore, it has the trained people to make it all happen. This company's expertise doesn't just apply to safety trials, either. It can help clients with every rung on the drug approval ladder — from helping answer basic questions to developing and running clinical trials, to overseeing the safety monitoring programs for drugs and devices once they've launched. Paying Off Handsomely This full-service approach is paying off handsomely. It's why this company's outlook for this year is around $1.7 billion in sales, a nearly 19% jump from last year (and much higher than Wall Street forecast). As a contractor, this company makes money throughout the entire trial and approval process, no matter if the drug beats the odds and makes it to the market. Thanks to this setup, this company is an earnings powerhouse. Over the past three years, it's grown its per-share profits ("PSP") by an average of 32%. In the most recent quarter, it grew PSP by nearly 60%. Even taking a conservative approach, I'm forecasting this company's earnings to double in a little over two years. And rest assured, its stock price could double just as quickly. If you're a "Pro" subscriber, I'll reveal the name of this exciting CRO, just a week before its latest earnings report is due and its stock could be ready to jump. So don't miss out!   FOR TREND TRADER PRO READERS ONLY > [LEARN MORE]( < Cheers and Good Investing, [Michael Robinson] Michael Robinson Chief Investment Officer Trend Trader Daily   Copyright © Trend Trader Daily, All rights reserved. You signed up on []( Our mailing address is: Trend Trader Daily 301 S. Perimeter Park Dr. Suite 100 Nashville, Tennessee 37211 [Update Subscription Preferences]( | [Unsubscribe from this list]( RISK NOTICE: All investing comes with risk. That includes the investments teased in this letter. You should never invest more than you can afford to lose. Please use this research for the purpose that it's intended — as research only. You should consult a professional financial advisor before ever taking a position in any securities you see herein. DISCLAIMERS: The work included in this communication is based on diverse sources including SEC filings, current events, interviews, corporate press releases, and information published on funding platforms, but the views we express and the conclusions we reach are our own. As such, this content may contain errors, and any investments described in this content should be made only after reviewing the filings and/or financial statements of the company, and only after consulting with your investment advisor. Actual results may differ significantly from the results described herein. Furthermore, nothing published by Trend Trader Daily, Inc should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. Trend Trader Daily is an independent provider of education, information and research on publicly traded companies, and as such, it accepts no direct or indirect compensation from any companies or third parties mentioned in any of our letters, reports or updates.